To arrive at consensus for candidate outcomes for disease activity assessment in large-vessel vasculitis (LVV) in clinical trials.
A Delphi survey including 99 items was circulated among international experts for 3 rounds.
Fifty-seven items were accepted for both giant cell arteritis and Takayasu arteritis. Sixty-seven percent of experts voted to have a common approach for both diseases with additional disease-specific items such as weight loss, scalp tenderness/necrosis, morning stiffness, dizziness, visual symptoms, and imaging.
This study highlights similarities and differences in experts’ perspectives for assessing clinical activity in LVV and may guide a consensus-driven core set of validated outcomes.